Roy Jensen

Roy Jensen, M.D., is a

• Professor at the Department of Pathology & Laboratory Medicine
• Director of the University of Kansas Cancer Center
• Director of the Kansas Masonic Research Institute
• Chief Executive Officer of the Midwest Cancer Alliance
• Holder of the William R. Jewell, MD Distinguished Kansas Masonic Professorship in Cancer Research

at the University of Kansas Medical Center, School of Medicine.

Education:

• MD, Vanderbilt University
• BS, Pittsburg State University

Research Interests focus on the expression and function of BRCA1 in breast tumorigenesis, extending to molecular mechanisms in various cancers (ovarian, pancreatic, head and neck), tumor microenvironment interactions, and translational applications in gene therapy, metabolic reprogramming, and immune evasion. His work often bridges genetics, cell biology, and clinical oncology.

Article Trends highlight investigations into BRCA1's systemic effects, kinase inhibitors (MK2, FGFR, XPO1), immune modulation (NKG2D, CXCL5), mitochondrial metabolism, and statistical innovations for clinical trial design. Key subfields include oncogenic signaling, chemoresistance, and precision medicine.

Scientific Recognition includes the William R. Jewell, MD Distinguished Kansas Masonic Professorship in Cancer Research, reflecting his leadership in cancer genetics and translational studies.

Additional Roles involve executive leadership, lab-based research (Jensen Lab), and collaborations in computational bioengineering, clinical trials, and public health initiatives related to geospatial cancer trends and health equity.